Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
MALVERN, Pa., Nov. 22, 2016 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced that management will host investor meetings during:
- Citi’s 2016 Global Healthcare Conference in New York, NY on Thursday, December 8, 2016
- Guggenheim’s 2016 Annual Healthcare Conference in Boston, MA on Tuesday, December 13, 2016
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting Aclaris’ website at www.aclaristx.com.
Contact: Aclaris Contact Michael Tung, M.D. Vice President / Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
